A versatile, scalable and robust AI-enabled drug discovery platform built with expert scientists, leveraging multi-modal data foundations.

End-to-end Drug Discovery

Explore opportunities

The Benevolent PlatformTM integrates technology, processes, and humans for faster and higher-quality R&D success

  • Technology tailored for discovery with:
    • Unique data foundations from multiple data types curated and purpose-built for drug discovery
    • Explainable AI models that enable scientists to see rationale for predictions
    • Applications across therapeutic areas and modalities
  • Precision workflows merge the strengths of AI & data analytics with insights derived from scientists’ strategic oversight and intuition
  • R&D Experts employ the tools to ensure that deep domain expertise guides every phase of development
BenAI Engine.png

AI FOUNDATIONS

BenAI Engine

BenAI Engine is the core foundation of our technology that turns fragmented scientific data into actionable insights. 
It is designed to ingest, organise, and leverage biomedical data for a nuanced understanding of disease biology. 

Learn more

BENEFITS

Proven to enhance drug discovery

Benefit-1.svg
DISEASE AGNOSTIC

We can work on any therapeutic area due to the breadth and diversity of our data foundations.

Benefit-2.svg
MODALITY AGNOSTIC

The Benevolent Platform™ can be applied to antibody and biologic targets, in addition to small molecule targets, to further diversify our portfolio.

Benefit-3.svg
IDENTIFIES NOVEL TARGETS

Our predictive tools can surface targets that have never been considered for a disease before – and spark creativity in scientists.

Benefit-4.svg
ACCELERATES DISCOVERY

Through the combined capabilities of our AI Platform, scientific expertise and wet lab facilities we can rapidly identify and validate targets and reduce drug development timelines.

Benefit-5.svg
BUILT FOR SCALE

Our scalable, repeatable approach can support multiple in-house drug programmes and commercial collaborations.

Benefit-6.svg
POTENTIAL TO INCREASE PROBABILITY OF SUCCESS

Scientists use our tools to build higher confidence hypotheses in the earliest stages of drug discovery, with the aim of reducing costly failures down the line.

What We do - Wet Labs.jpg

WET LABS

In-house wet labs reduce development timelines

Our fully equipped laboratories in Cambridge (UK), and drug discovery team can rapidly progress programmes leveraging our cutting-edge technologies such as CRISPR, RNA-seq and human iPSCs.

PARTNERING

We partner with leading pharmaceutical and biotech companies to help them unlock biological insights and tackle complex therapeutic challenges.

Speak to our team